Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) – Analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Homology Medicines in a research note issued on Thursday, March 16th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.17 per share for the year, down from their prior forecast of $0.28. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Homology Medicines’ current full-year earnings is ($2.00) per share.
Homology Medicines Price Performance
Shares of NASDAQ FIXX opened at $0.95 on Friday. The company has a market capitalization of $54.80 million, a price-to-earnings ratio of -8.64 and a beta of -0.01. The business has a 50-day moving average of $1.47 and a two-hundred day moving average of $1.54. Homology Medicines has a 1 year low of $0.95 and a 1 year high of $3.57.
Institutional Trading of Homology Medicines
About Homology Medicines
Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.
- Get a free copy of the StockNews.com research report on Homology Medicines (FIXX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.